TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03430882
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT03430882
Drug: Sapanisertib
Normalized name: SAPANISERTIB
DrugBank: Sapanisertib (DB11836)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given PO
Study: NCT01819922
Drug: PF-05175157
Normalized name: PF-05175157
DrugBank: PF-05175157 (DB12096)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg as powder in capsule, one dose within 5 minutes prior to AM meal
Study: NCT02926573
Drug: Gabapentin
Normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01543451
Drug: Elsiglutide
Normalized name: Elsiglutide
DrugBank: Elsiglutide (DB06336)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24 mg administered s.c. once daily for 4 consecutive days from Day 1 chemotherapy
Study: NCT00000246
Drug: Flumazenil
Normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04015908
Drug: Pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin 50 mg
Study: NCT04015908
Drug: Oxycodone
Normalized name: Oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oxycodone 5-10 mg
Study: NCT04015908
Drug: Percocet
Normalized name: Percocet
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Percocet (oxycodone 5mg/acetaminophen 325 mg)
Study: NCT00984464
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6 AUC mg/ml min, 30-min intravenous infusion, given on Day 1 of a 21-day cycle
Study: NCT03769714
Drug: Exparel
Normalized name: Exparel
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Exparel (bupivacaine liposome injectable suspension) is a liposome injection of bupivacaine, an amide-type local anesthetic, indicated (bupivacaine liposome injectable suspension) for administration into the surgical site to produce postsurgical analgesia.
Study: NCT01722422
Drug: oxygen and saline
DrugBank: Oxygen (DB09140)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00984464
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 200 mg/m2, 3-hour intravenous infusion, given on Day 1 of a 21-day cycle
Study: NCT02021500
Drug: ABI-007
Normalized name: ABI-007 COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: No intervention is being given in this extension study which is gathering survival information on participants of study NCT 00844649 (Celgene study CA046) who were known to be alive as of March 2013)
Study: NCT03397797
Drug: Rocuronium
Normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In the group to need the eletrophysiological monitoring during the operation, we don't inject muscle relaxant except anestheitic induction.
Study: NCT03250676
Drug: H3B-6545
Normalized name: H3B-8800
DrugBank: H3B-8800 (DB14017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules by mouth once daily
Study: NCT00611455
Drug: ofatumumab
Normalized name: Ofatumumab
DrugBank: Ofatumumab (DB06650)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two 700mg IV infusions taken 14 days apart. A total of 8 infusions cycles given over a 144 week period
Study: NCT02676310
Drug: Bimatoprost
Normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02792699
Drug: ABP 798
Normalized name: ABPC
DrugBank: Ampicillin (DB00415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Supplied as a 10 mg/mL liquid concentrate for intravenous (IV) administration.
Study: NCT02792699
Drug: Rituximab (US)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Supplied as a 10 mg/mL liquid concentrate for IV administration.
Study: NCT02792699
Drug: Rituximab (EU)
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Supplied as a 10 mg/mL liquid concentrate for IV administration.
Study: NCT01582152
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Arm A + B: 10 mg/kg by vein every 2 weeks of a 42 day cycle.
Study: NCT00205504
Drug: Ortho Tri Cyclen
Normalized name: Ortho Tri Cyclen KIT
DrugBank: Norgestimate (DB00957)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ortho Tri Cyclen, one tablet daily, for 6 cycles
Study: NCT02169310
Drug: [11C] Raclopride
DrugBank: Raclopride (DB12518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: \[11C\] Raclopride is administered under an IND 054135. This IND is sponsored by the NIH Clinical Center and \[11C\] Raclopride is dispensed by the NIH PET Department. Quality Assurance for Radioactive Drug: \[11C\] Raclopride, is assayed for radiochemical purity under the supervision of the NIH PET Department prior to dispensing the drug for administration. Given that IND PET drugs manufactured at the NIH PET Department are used in a single site and that there is no intent for their commercialization, submission of IBs has not been required by FDA for any of the NIH Office of Research Support and Compliance-sponsored IND applications.
Study: NCT03537768
Drug: Ulipristal Acetate
Normalized name: Ulipristal Acetate
DrugBank: Ulipristal (DB08867)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: UPA Tablet
Study: NCT03537768
Drug: Levonorgestrel
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LNG Tablet
Study: NCT03537768
Drug: Levonorgestrel
Normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: LNG Tablet (x2)
Study: NCT03709888
Drug: Memantine XR-pregabalin combination therapy
Normalized name: memantine Extended Release Oral Capsule
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pregabalin and memantine XR work in different pathways and are approved by the U.S. Food and Drug Administration for various indications. Both medications have an established safety profile and have demonstrated improvement on neuropathy-related symptoms.
Study: NCT01849250
Drug: Docosahexaenoic Acid
Normalized name: docosahexaenoic acid
DrugBank: Doconexent (DB03756)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00008294
Drug: dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00008294
Drug: floxuridine
Normalized name: Floxuridine
DrugBank: Floxuridine (DB00322)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00008294
Drug: oxaliplatin
Normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04180813
Drug: Linagliptin
Normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: drug
Study: NCT04180813
Drug: Acarbose
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: drug
Study: NCT04635696
Drug: Ethyl chloride
Normalized name: Ethyl Chloride
DrugBank: Ethyl chloride (DB13259)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pressurized vapocoolant developed for acute, mild pain relief.
Study: NCT02805907
Drug: Calcifediol
Normalized name: Calcifediol
DrugBank: Calcifediol (DB00146)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00006386
Drug: carmustine
Normalized name: Carmustine
DrugBank: Carmustine (DB00262)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00729118
Drug: lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: combined with Vorinostat (SAHA) days 1-21 of a 28-day cycle until progression or clinically significant toxicity.
Study: NCT00729118
Drug: vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vorinostat (SAHA) will be administered orally beginning at dose level 1 starting day +90 ±6 days after HSCT for days 1 and 15-21 of a 28-day cycle combined with lenalidomide days 1-21 of a 28-day cycle until progression or clinically significant toxicity.
Study: NCT00114114
Drug: Goserelin acetate
Normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3.6 gms sc every 4 weeks
Study: NCT01264965
Drug: long acting oxycodone
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10mg twice daily
Study: NCT01264965
Drug: extra strength acetaminophen
Normalized name: Extra Strength Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg twice daily
Study: NCT02237495
Drug: dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexmedetomidine with the dose of 0.4 ug/kg/h is continuously infused right after anesthesia induction and lasts for 12 hrs.
Study: NCT02508168
Drug: Alogliptin
Normalized name: Alogliptin
DrugBank: Alogliptin (DB06203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Alogliptin 12.5 mg tablets
Study: NCT04199117
Drug: Varenicline
Normalized name: Varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants randomized to intensive treatment who choose to use this intervention will receive one 0.5 mg pill for the first 3 days, starting 7 days prior to the target quit day (TQD). They will then use one 0.5 mg pill twice daily for the next 4 days. After the first week of study medication ramp up, participants will use one 1 mg pill twice daily until 11 weeks post-TQD. This will not be used at the same time as combination nicotine replacement therapy.
Study: NCT04199117
Drug: Combination nicotine patch and nicotine mini-lozenge treatment
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants randomized to intensive treatment who choose to use this intervention will receive 12 weeks of nicotine patches and nicotine mini-lozenges starting on the target quit day (TQD). Participants who smoke more than 10 cigarettes/day will start with a 21 mg patch for 8 weeks, and then titrate down to a 14 mg patch for 2 weeks and then a 7 mg patch for 2 weeks. Participants who smoke 5-10 cigarettes/day will be given 10 weeks of 14 mg patches and then 2 weeks of 7 mg patches. Participants will receive 2 mg mini-lozenges for use starting on the target quit date and the following 12 weeks. Participants will be instructed to use 9-20 mini-lozenges per day (one every 1-2 hours) for the first 6 weeks, then reduce to a mini-lozenge every 2-4 hours for 3 weeks, and then a mini-lozenge every 4-8 hours for 3 weeks. Combination nicotine patch and nicotine mini-lozenge treatment will not be used at the same time as varenicline.
Study: NCT02508168
Drug: Metformin Hydrochloride
Normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Metformin hydrochloride 1000 mg tablets
Study: NCT00495560
Drug: Addition of misoprostol 25 mcg 12 hours before induction
Normalized name: misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol given buccally the night before induction
Study: NCT03593304
Drug: Injection Mecobalamin
Normalized name: mecobalamin Injectable Solution
DrugBank: Mecobalamin (DB03614)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection Mecobalamin (500mcg) three times a week (on day 1,3,5 of vincristine chemotherapy) for 5 weeks.
Study: NCT00848692
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart
Study: NCT00848692
Drug: Saline (NaCl 0,9 %) (placebo)
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Two infusions of saline (NaCl 0,9 %) given two weeks apart
Study: NCT00602316
Drug: gadolinium-chelate
DrugBank: Gadolinium (DB12091)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01172288
Drug: N-Acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 600mg capsule twice a day for 2 weeks and then 2 600mg capsules twice a day for the remaining 10 weeks of the trial.
Study: NCT02192710
Drug: Midazolam oral intake
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03288584
Drug: Tocilizumab (Actemra®)
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Inhibition of Interleukin-6 activity by tocilizumab (Actemra®) 150mg od, sc injection
Study: NCT03288584
Drug: Other biological agent
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other biological agent (TNFa inhibitor, abatacept, rituximab, IL-1Ra)
Study: NCT00596518
Drug: PF-00734200
Normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The drug is administered as a single dose of four 5-mg tablets
Study: NCT04343885
Drug: 177Lu-PSMA-617
Normalized name: 177Lu-PSMA-617
DrugBank: Lutetium Lu-177 vipivotide tetraxetan (DB16778)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given 7.5GBq of 177Lu-PSMA every 6 weeks for 2 cycles.
Study: NCT04343885
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m2 given every 3 weeks for 6 cycles
Study: NCT00717418
Drug: cyclosporine ophthalmic emulsion 0.05%, artificial tears
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: one drop, twice a day in each eye
Study: NCT01734993
Drug: Tocilizumab
Normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Participants will receive TCZ 162 milligrams (mg) SC injection once a week.
Study: NCT02619253
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT02619253
Drug: Vorinostat
Normalized name: Vorinostat
DrugBank: Vorinostat (DB02546)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00085384
Drug: PEG-interferon alfa-2b
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Biological/Vaccine: PEG-interferon alfa-2b~Dose 1.25 mg/kg/week given subcutaneously
Study: NCT04037358
Drug: Radium-223
Normalized name: Radium-223
DrugBank: Radium Ra-223 (DB12813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radium-223 plus SABR will be within two weeks.
Study: NCT02436486
Drug: ldalopirdine 120 mg
Normalized name: Idalopirdine
DrugBank: Idalopirdine (DB11957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two 60 mg encapsulated film-coated tablets, orally, single dose
Study: NCT02436486
Drug: Idalopirdine 360 mg
Normalized name: Idalopirdine
DrugBank: Idalopirdine (DB11957)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four 90 mg encapsulated film-coated tablets, orally, single dose
Study: NCT02436486
Drug: Moxifloxacin 400 mg
Normalized name: moxifloxacin 400 MG
DrugBank: Moxifloxacin (DB00218)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Encapsulated tablets, orally, single dose
Study: NCT02933762
Drug: JNJ-54175446
Normalized name: JNJ-54175446
DrugBank: JNJ-54175446 (DB15358)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.
Study: NCT01536938
Drug: Calcipotriol
Normalized name: Calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01536938
Drug: Betamethasone
Normalized name: Betamethasone
DrugBank: Betamethasone (DB00443)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02820610
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 mg/kg bupivacaine 0.5% and 1 ug/kg of dexamedetomidine diluted in normal saline 0.9 % will instilled into the peritoneal cavity
Study: NCT02820610
Drug: Magnesium Sulfate
Normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 mg/kg bupivacaine 0.5% and 30 mg/kg of magnesium sulfate diluted in normal saline 0.9 % will instilled into the peritoneal cavity
Study: NCT03586843
Drug: JNJ-64565111
Normalized name: JNJ-64565111
DrugBank: Efinopegdutide (DB15077)
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-64565111 SC will be administered on Day 1 of Treatment Periods 1, 2 and 3 as per the assigned treatment sequence in Part A and as ascending doses on Days 1, 8, 15, 22, 29 and 36 in Part B.
Study: NCT02237807
Drug: DIRITHROMYCIN 500 MG ENTERIC COATED TABLET
Normalized name: dirithromycin
DrugBank: Dirithromycin (DB00954)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02237807
Drug: DYNABAC 250 MG ENTERIC COATED TABLET
Normalized name: dirithromycin
DrugBank: Dirithromycin (DB00954)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00984802
Drug: CMX-2043
Normalized name: CMX-2043
DrugBank: CMX-2043 (DB12795)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for IV administration at 0.8, 1.6 or 2.4 mg/kg single dose.
Study: NCT01943864
Drug: Trametinib (single tablet)
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The drug substance is blended with inert
Study: NCT01943864
Drug: Trametinib (Multiple tablet)
Normalized name: Trametinib
DrugBank: Trametinib (DB08911)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: The drug substance is blended with inert
Study: NCT02494349
Drug: Solifenacin 5mg+Tamsulosin 0.2mg
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The subjects will receive Solifenacin 5mg and Tamsulosin 0.2mg under fed(high fat meal) condition. After washout period, the subjects will receive JLP-1207 under fed(high fat meal) condition.
Study: NCT00374907
Drug: Saxagliptin
Normalized name: Saxagliptin
DrugBank: Saxagliptin (DB06335)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet, Oral, 5 mg, Once daily, (up to 12 weeks ST, up to 104 weeks LT)
Study: NCT00374907
Drug: Metformin (blinded)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablet, Oral, 500 mg titrated to 1000 mg, Once daily (up to 104 weeks LT, starting at Week 12)
Study: NCT00374907
Drug: Metformin (open-label)
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, 500-1500 mg, as needed (starting in LT)
Study: NCT00856375
Drug: irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: IV every 3 weeks
Study: NCT01271478
Drug: captopril plus placebo
DrugBank: Captopril (DB01197)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: This group will receive captopril 50 mg/day (1 tablet of 25 mg orally twice a day) plus 1 tablet of placebo orally twice a day
Study: NCT01271478
Drug: Telmisartan plus Captopril
Normalized name: Captopril
DrugBank: Telmisartan (DB00966)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients of this group will receive captopril 50 mg/day (1 tablet 25 mg orally twice a day) plus telmisartan 80 mg/day (1 tablet 40 mg orally twice a day)
Study: NCT01270893
Drug: Nilotinib
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400 mg by mouth twice a day for 7 days. Patients on Arm 2 will continue to receive Nilotinib until they have disease progression or are resectable.
Study: NCT02549677
Drug: Epirubicin
Normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: epirubicin, 90mg per square meter, every 3 weeks, day 1
Study: NCT02549677
Drug: Docetaxel
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: docetaxel, 75mg per square meter, every 3 weeks, day 1
Study: NCT00698126
Drug: biphasic insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Observational study; use of the products as in the normal clinical practice conditions
Study: NCT00222729
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg/m2 day 1 q 21 days
Study: NCT00222729
Drug: Bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 15 mg/kg IV q 21 days following pemetrexed
Study: NCT01105871
Drug: naloxone
Normalized name: Naloxone
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 mg naloxone in 10 ml saline given iv bolus
Study: NCT00278265
Drug: MTX followed by fludarabine
DrugBank: Fludarabine (DB01073)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX should be administered with 10-20mg weekly, calculated according to the body weight. Fludarabine should be administered with 25mg/m2 on day 1-3 of 28 days, up to 4 cycles
Study: NCT03395340
Drug: Ruxolitinib 1.5% cream
Normalized name: RUXOLITINIB 1.5% CREAM,TOP
DrugBank: Ruxolitinib (DB08877)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical formulation of ruxolitinib, a Janus kinases (JAK) 1/2 inhibitor.
Study: NCT02492750
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT02492750
Drug: Lenalidomide
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT01293396
Drug: Insulin Aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients received insulin aspart before breakfast and before lunch.
Study: NCT01293396
Drug: Insulin Aspart 30
Normalized name: insulin degludec 70 UNT/ML / insulin aspart 30 UNT/ML in 3 ML Pen Injector
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients received biphasic insulin aspart 30 before breakfast and before lunch.
Study: NCT01293396
Drug: Insulin Aspart 70
Normalized name: insulin aspart protamine / insulin aspart 70/30 in 3 ML Pen Injector
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Patients received biphasic insulin aspart 70 before breakfast and before lunch.
Study: NCT01391312
Drug: normal saline (placebo)
Normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (placebo) injected into the glabellar region on Day 0.
Study: NCT00002141
Drug: Abacavir sulfate
Normalized name: Abacavir Sulfate
DrugBank: Abacavir (DB01048)
Approvals — FDA: yes, EMA: yes, PMDA: no